C. Krieckaert

1.9k total citations
44 papers, 1.1k citations indexed

About

C. Krieckaert is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, C. Krieckaert has authored 44 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Rheumatology, 21 papers in Immunology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in C. Krieckaert's work include Rheumatoid Arthritis Research and Therapies (30 papers), Systemic Lupus Erythematosus Research (12 papers) and Biosimilars and Bioanalytical Methods (11 papers). C. Krieckaert is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (30 papers), Systemic Lupus Erythematosus Research (12 papers) and Biosimilars and Bioanalytical Methods (11 papers). C. Krieckaert collaborates with scholars based in Netherlands, Spain and United States. C. Krieckaert's co-authors include Gertjan Wolbink, Michael T. Nurmohamed, Theo Rispens, Lucien A. Aarden, Desirée van der Kleij, Willem F. Lems, E. Kneepkens, Anna Jamnitski, Mieke F. Pouw and Ben A. C. Dijkmans and has published in prestigious journals such as PLoS ONE, Annals of the Rheumatic Diseases and Nature Reviews Rheumatology.

In The Last Decade

C. Krieckaert

43 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Krieckaert Netherlands	16	702	578	328	212	166	44	1.1k
Guro Løvik Goll Norway	13	581 0.8×	252 0.4×	184 0.6×	96 0.5×	71 0.4×	50	831
Julie Zrubek United States	7	901 1.3×	574 1.0×	79 0.2×	561 2.6×	131 0.8×	7	1.2k
Allison Luo United States	13	343 0.5×	416 0.7×	92 0.3×	160 0.8×	80 0.5×	30	1.0k
L Pallarés Spain	16	842 1.2×	457 0.8×	218 0.7×	151 0.7×	53 0.3×	26	1.1k
A Daragon France	18	584 0.8×	182 0.3×	177 0.5×	183 0.9×	79 0.5×	66	946
Alejandro Villalba Spain	15	387 0.6×	325 0.6×	114 0.3×	65 0.3×	57 0.3×	27	635
J Lysholm Sweden	9	613 0.9×	273 0.5×	122 0.4×	232 1.1×	139 0.8×	20	990
Zuhre Tutuncu United States	10	821 1.2×	585 1.0×	51 0.2×	378 1.8×	88 0.5×	15	1.1k
Ferdinand C. Breedveld Netherlands	8	727 1.0×	215 0.4×	108 0.3×	315 1.5×	155 0.9×	10	990
Shouvik Dass United Kingdom	13	568 0.8×	487 0.8×	262 0.8×	106 0.5×	227 1.4×	36	1.1k

Countries citing papers authored by C. Krieckaert

Since Specialization

Citations

This map shows the geographic impact of C. Krieckaert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Krieckaert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Krieckaert more than expected).

Fields of papers citing papers by C. Krieckaert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Krieckaert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Krieckaert. The network helps show where C. Krieckaert may publish in the future.

Co-authorship network of co-authors of C. Krieckaert

This figure shows the co-authorship network connecting the top 25 collaborators of C. Krieckaert. A scholar is included among the top collaborators of C. Krieckaert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Krieckaert. C. Krieckaert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boekel, Laura, Femke Hooijberg, Floris C. Loeff, et al.. (2024). POS0017 SUCCESSFUL THERAPEUTIC DRUG MONITORING BASED ADALIMUMAB DOSE REDUCTION IN RHEUMATOID ARTHRITIS PATIENT WITH LOW DISEASE ACTIVITY (ADDORA-LOW): A SINGLE BLIND, NON-INFERIORITY, RANDOMIZED CLINICAL TRIAL. Annals of the Rheumatic Diseases. 83. 450–450. 1 indexed citations

Krieckaert, C., Borja Hernández‐Breijo, Johanna Elin Gehin, et al.. (2022). Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. RMD Open. 8(2). e002216–e002216. 16 indexed citations

Boekel, Laura, Femke Hooijberg, Erik H Vogelzang, et al.. (2022). COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases. The Lancet Rheumatology. 4(5). e310–e313. 12 indexed citations

Vogelzang, Erik H, et al.. (2018). Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. PLoS ONE. 13(10). e0205125–e0205125. 13 indexed citations

Krieckaert, C., Michael T. Nurmohamed, Ronald van Vollenhoven, et al.. (2017). Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Annals of the Rheumatic Diseases. 77(4). 484–487. 53 indexed citations

Plasencia, Chamaida, E. Kneepkens, Gertjan Wolbink, et al.. (2015). Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity. The Journal of Rheumatology. 42(9). 1638–1646. 29 indexed citations

Vogelzang, Erik H, E. Kneepkens, Michael T. Nurmohamed, et al.. (2014). SAT0391 A Diminished Clinical Response at 28 and 52 Weeks of Adalimumab Treatment in Patients with Psoriatic Arthritis is Associated with Anti-Drug Antibodies. Annals of the Rheumatic Diseases. 73. 735–736. 3 indexed citations

Kneepkens, E., C. Krieckaert, Desirée van der Kleij, et al.. (2014). Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Annals of the Rheumatic Diseases. 74(10). 1825–1829. 43 indexed citations

Vogelzang, Erik H, E. Kneepkens, Michael T. Nurmohamed, et al.. (2014). Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Annals of the Rheumatic Diseases. 73(12). 2178–2182. 58 indexed citations

10.

Krieckaert, C., Sandhya Nair, Michael T. Nurmohamed, et al.. (2013). Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Annals of the Rheumatic Diseases. 74(2). 361–368. 77 indexed citations

11.

Kneepkens, E., James Cheng‐Chung Wei, Michael T. Nurmohamed, et al.. (2013). Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Annals of the Rheumatic Diseases. 74(2). 396–401. 67 indexed citations

12.

Schouwenburg, Pauline A. van, C. Krieckaert, Theo Rispens, et al.. (2013). Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Annals of the Rheumatic Diseases. 72(10). 1680–1686. 75 indexed citations

13.

Krieckaert, C., Anna Jamnitski, Michael T. Nurmohamed, et al.. (2012). Comparison of long‐term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis & Rheumatism. 64(12). 3850–3855. 54 indexed citations

14.

Krieckaert, C., Michael T. Nurmohamed, Gertjan Wolbink, & Willem F. Lems. (2012). Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Lara D. Veeken. 52(3). 547–553. 59 indexed citations

15.

Krieckaert, C. & Willem F. Lems. (2012). Biologicals and bone loss. Therapeutic Advances in Musculoskeletal Disease. 4(4). 245–247. 3 indexed citations

16.

Schouwenburg, Pauline A. van, C. Krieckaert, Michael T. Nurmohamed, et al.. (2012). IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients. Journal of Clinical Immunology. 32(5). 1000–1006. 59 indexed citations

17.

Krieckaert, C., Theo Rispens, & Gertjan Wolbink. (2012). Immunogenicity of biological therapeutics. Current Opinion in Rheumatology. 24(3). 306–311. 58 indexed citations

18.

Bartelds, G. M., C. Krieckaert, Franktien Turkstra, et al.. (2011). Venous and arterial thromboembolic events in adalimumab‐treated patients with antiadalimumab antibodies: A case series and cohort study. Arthritis & Rheumatism. 63(4). 877–883. 91 indexed citations

19.

Jamnitski, Anna, C. Krieckaert, Michael T. Nurmohamed, et al.. (2011). Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Annals of the Rheumatic Diseases. 71(1). 88–91. 112 indexed citations

20.

Krieckaert, C., G. M. Bartelds, & Gertjan Wolbink. (2010). Immunogenicity of biologic therapies—we need tolerance. Nature Reviews Rheumatology. 6(10). 558–559. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact